Calidi Biotherapeutics, Inc.
CLDI
$0.18
$0.00-1.30%
AMEX
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -21.55% | -12.50% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -11.53% | -10.88% | |||
| Operating Income | 11.53% | 10.88% | |||
| Income Before Tax | 21.47% | 10.18% | |||
| Income Tax Expenses | -120.00% | 150.00% | |||
| Earnings from Continuing Operations | 21.66% | 10.07% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -90.63% | -30.43% | |||
| Net Income | 21.23% | 9.90% | |||
| EBIT | 11.53% | 10.88% | |||
| EBITDA | 36.36% | 0.31% | |||
| EPS Basic | 74.18% | -11.02% | |||
| Normalized Basic EPS | 42.13% | 47.19% | |||
| EPS Diluted | 74.18% | -11.02% | |||
| Normalized Diluted EPS | 42.13% | 47.19% | |||
| Average Basic Shares Outstanding | 45.14% | 70.56% | |||
| Average Diluted Shares Outstanding | 45.14% | 70.56% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||